For in vitro diagnostic use. Nucleus Others Estrogen Receptor SP1 CONFIRM IVD Breast CONFIRM anti-Estrogen Receptor (ER) (SP1) Rabbit Monoclonal Primary Antibody PID00000060 Rabbit SP1 05278406001 CONFIRM ANTI-ER (SP1) CONFIRM anti-Estrogen Receptor (ER) (SP1) Rabbit Monoclonal Primary Anti body 04015630972241 Reagents, kits 790-4324 50 tests Not Available true 05278414001 CONFIRM ANTI-ER (SP1) PRIMARY ANTIBODY CONFIRM anti-Estrogen Receptor (ER) (SP1) Rabbit Monoclonal Primary Anti body 04015630972234 Reagents, kits 790-4325 250 tests Not Available true Le CONFIRM anti-Estrogen Receptor (ER) (SP1) Rabbit Monoclonal Primary Antibody (anticorps CONFIRM anti-ER [SP1]) est destiné à être utilisé en laboratoire pour la détection qualitative d’un antigène du récepteur des œstrogènes (ER) dans des coupes de tissus mammaires fixés au formol et inclus en paraffine colorées sur un automate de coloration VENTANA avec les kits de détection et les réactifs auxiliaires VENTANA. L’anticorps CONFIRM anti-ER (SP1) est dirigé contre un épitope présent sur l’ER alpha humain localisé dans le noyau des cellules normales et néoplasiques ER positives. L’anticorps CONFIRM anti-ER (SP1) est indiqué pour faciliter la prise en charge, le pronostic et la prédiction du résultat du traitement endocrinien du carcinome du sein.Ce produit doit être interprété par un anatomopathologiste qualifié, en complément d’examens histologiques, d’informations cliniques pertinentes et de contrôles adaptés.Utilisation uniquement sur ordonnance.Cet anticorps est conçu pour une utilisation en diagnostic in vitro (IVD). fr CONFIRM anti-ER (SP1) antibody binds to ER in formalin-fixed, paraffin-embedded (FFPE) tissue sections. The specific antibody can be localized by either a biotin conjugated secondary antibody formulation that recognizes rabbit immunoglobulins, followed by the addition of a streptavidin horseradish peroxidase (HRP) conjugate (iVIEW DAB Detection Kit) or a secondary antibody-HRP conjugate (ultraView Universal DAB Detection Kit). The specific antibody-enzyme complex is then visualized with a precipitating enzyme reaction product. Clinical cases should be evaluated within the context of the performance of appropriate controls. Ventana recommends the inclusion of a positive tissue control fixed and processed in the same manner as the patient specimen (for example, a weakly positive breast carcinoma or uterus). In addition to staining with CONFIRM anti-ER (SP1) antibody, a second slide should be stained with CONFIRM Negative Control Rabbit Ig. For the test to be considered valid, the positive control tissue should exhibit nuclear staining of the tumor cells or uterine glands and stroma. These components should be negative when stained with CONFIRM Negative Control Rabbit Ig. In addition, it is recommended that a negative tissue control slide (for example, an ER negative breast carcinoma) be included for every batch of samples processed and run on a BenchMark IHC/ISH instrument. This negative tissue control should be stained with CONFIRM anti-ER (SP1) antibody to ensure that the antigen enhancement and other pretreatment procedures did not create false positive staining. en